Granulosa cell tumor with activated mTOR-HIF-1α-VEGF pathway

Journal of Obstetrics and Gynaecology Research

Volumn 36, Issue 2, 2010, Pages 448-453

  Miyazawa, Masaki ^a   Yasuda, Masanori ^b   Fujita, Mariko ^a   Hirabayashi, Kenichi ^a   Hirasawa, Takeshi ^a   Kajiwara, Hiroshi ^a   Muramatsu, Toshinari ^a   Miyazaki, Sayuri ^c   Harasawa, Makiko ^a   Matsui, Naruaki ^a   Ogane, Naoki ^d   Murakami, Masaru ^a   Mikami, Mikio ^a   Yanase, Toshihiko ^e   Osamura, R Yoshiyuki ^a  

^a TOKAI UNIVERSITY   (Japan)

^b SAITAMA MEDICAL UNIVERSITY   (Japan)

^c Ebina General Hospital   (Japan)

^d KANAGAWA CANCER CENTER   (Japan)

^e KYUSHU UNIVERSITY   (Japan)

Author keywords

Granulosa cell tumor; HIF 1 ; MTOR; Rapamycin

Indexed keywords

ESTRADIOL; EVEROLIMUS; FOLLITROPIN; HYPOXIA INDUCIBLE FACTOR 1ALPHA; LUTEINIZING HORMONE; MAMMALIAN TARGET OF RAPAMYCIN; PHOSPHOPROTEIN; PROGESTERONE; PROLACTIN; TUMOR MARKER; VASCULOTROPIN;

ABDOMINAL HYSTERECTOMY; ADULT; AGED; ARTICLE; CANCER INHIBITION; CLINICAL ARTICLE; DNA BINDING; DOWN REGULATION; ENZYME ACTIVATION; FEMALE; GENE EXPRESSION PROFILING; GENITAL BLEEDING; GRANULOSA CELL TUMOR; HISTOPATHOLOGY; HORMONE DETERMINATION; HUMAN; HUMAN CELL; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; IN VITRO STUDY; PROTEIN EXPRESSION; PROTEIN TARGETING; TRANSVAGINAL ECHOGRAPHY; TUMOR GROWTH; UTERINE CERVIX CYTOLOGY; WESTERN BLOTTING;

ADULT; AGED; BLOTTING, WESTERN; CELL LINE, TUMOR; FEMALE; GRANULOSA CELL TUMOR; HUMANS; HYPOXIA-INDUCIBLE FACTOR 1, ALPHA SUBUNIT; IMMUNOHISTOCHEMISTRY; INTRACELLULAR SIGNALING PEPTIDES AND PROTEINS; MIDDLE AGED; OVARIAN NEOPLASMS; PROTEIN-SERINE-THREONINE KINASES; SIGNAL TRANSDUCTION; VASCULAR ENDOTHELIAL GROWTH FACTOR A;

EID: 77950222705     PISSN: 13418076     EISSN: 14470756     Source Type: Journal    
DOI: 10.1111/j.1447-0756.2009.01127.x     Document Type: Article

References (21)

1. Hirota K, Semenza GL. Regulation of angiogenesis by hypoxia-inducible factor 1. Crit Rev Oncol Hematol 2006 59 : 15 26.
2. Jiang BH, Liu LZ. Role of mTOR in anticancer drug resistance: Perspectives for improved drug treatment. Drug Resist Updat 2008 11 : 63 76.
3. Mabuchi S, Altomare DA, Connolly DC et al. RAD001 (Everolimus) delays tumor onset and progression in a transgenic mouse model of ovarian cancer. Cancer Res 2007 67 : 2408 2413.
4. Miyazawa M, Yasuda M, Fujita M et al. Therapeutic strategy targeting at mTOR-HIF-1α-VEGF pathway for ovarian clear cell adenocarcinoma. Pathol Int 2009 59 : 19 27.
5. Pectasides D, Pectasides E, Economopoulos T. Systemic therapy in metastatic or recurrent endometrial cancer. Cancer Treat Rev 2007 33 : 177 190.
6. Boulay A, Rudloff J, Ye J et al. Dual inhibition of mTOR and estrogen receptor signaling in vitro induces cell death in models of breast cancer. Clin Cancer Res 2005 11 : 5319 5328.
7. Duran I, Kortmansky J, Singh D et al. A phase II clinical and pharmacodynamic study of temsirolimus in advanced neuroendocrine carcinomas. Br J Cancer 2006 95 : 1148 1154.
8. Atkins MB, Hidalgo M, Stadler WM et al. Randomized phase II study of multiple dose levels of CCI-779, a novel mammalian target of rapamycin kinase inhibitor, in patients with advanced refractory renal cell carcinoma. J Clin Oncol 2004 22 : 909 918.
9. Nishi Y, Yanase T, Mu Y et al. Establishment and characterization of a steroidogenic human granulosa-like tumor cell line, KGN, that expresses functional follicle-stimulating hormone receptor. Endocrinology 2001 142 : 437 445.
10. Schumer ST, Cannistra SA. Granulosa cell tumor of the ovary. J Clin Oncol 2003 21 : 1180 1189.
11. Semenza GL. HIF-1 and tumor progression: Pathophysiology and therapeutics. Trends Mol Med 2002 70 : 1841 1843.
12. Iida T, Yasuda M, Miyazawa M et al. Hypoxic status in ovarian serous and mucinous tumors: Relationship between histological characteristics and HIF-1alpha/GLUT-1 expression. Arch Gynecol Obstet 2008 277 : 539 546.
13. Yasuda M, Miyazawa M, Fujita M et al. Expression of hypoxia inducible factor-1alpha (HIF-1alpha) and glucose transporter-1 (GLUT-1) in ovarian adenocarcinomas: Difference in hypoxic status depending on histological character. Oncol Rep 2008 19 : 111 116.
14. Birner P, Schindl M, Obermair A, Breitenecker G, Oberhuber G. Expression of hypoxia-inducible factor 1alpha in epithelial ovarian tumors: Its impact on prognosis and on response to chemotherapy. Cancer Res 2000 60 : 4610 4616.
15. Miyazawa M, Yasuda M, Fujita M et al. Association of hypoxia-inducible factor-1 expression with histology in epithelial ovarian tumors: A quantitative analysis of HIF-1. Arch Gynecol Obstet 2008 279 : 789 796.
16. Trastour C, Benizri E, Ettore F et al. HIF-1alpha and CA IX staining in invasive breast carcinomas: Prognosis and treatment outcome. Int J Cancer 2007 120 : 1451 1458.
17. Chen YJ. Targeted mTOR in human gynecologic cancers. Cancer Mol 2007 3 : 101 106.
18. Awada A, Cardoso F, Fontaine C et al. The oral mTOR inhibitor RAD001 (everolimus) in combination with letrozole in patients with advanced breast cancer: Results of a phase I study with pharmacokinetics. Eur J Cancer 2008 44 : 84 91.
19. Jiang H, Feng Y. Hypoxia-inducible factor 1alpha (HIF-1alpha) correlated with tumor growth and apoptosis in ovarian cancer. Int J Gynecol Cancer 2006 16 : 405 412.
20. Treeck O, Wackwitz B, Haus U, Ortmann O. Effects of a combined treatment with mTOR inhibitor RAD001 and tamoxifen in vitro on growth and apoptosis of human cancer cells. Gynecol Oncol 2006 102 : 292 299.
21. Fujita M, Yasuda M, Kitatani K et al. An Up-to-Date Anti-Cancer Treatment Strategy Focusing on HIF-1alpha Suppression: Its Application for Refractory Ovarian Cancer. Acta Histochem Cytochem 2007 40 : 139 142.